Reduced Dose Pneumococcal Conjugate Vaccine Schedules: Closing the Knowledge Gap and Informing Immunization Policies in Thailand

The National Vaccine Institute (NVI), Thailand0 个研究点目标入组 1,050 人开始时间: 2023年9月29日最近更新: 2024年8月19日

试验速览

暂无简介。

•1)Female or male infants aged 2 months (plus/minus 7 days).
•2)Participants with normal birthweight.
•3)Participants born to HIV-uninfected mothers.
•4)Participants that have parent or legal caregiver capable of comprehending Thai (speaking, reading, writing) and abiding by protocol instructions.
•5)Participants that have parent or legal caregiver that are available throughout the trial period.
•6)Participants that have parent or legal caregiver willing to provide written inform consent to have their children participate in the clinical trial.

•1)Participants with severe illnesses, unmanageable symptoms, or underlying unstable disease.
•2)Participants with a history of pneumococcal disease (microbiologically confirmed).
•3)Participants with a history of severe drug or vaccine allergies (anaphylaxis), especially PCV or vaccines that contain diphtheria toxoid.
•4)Participants with Streptococcus pneumoniae vaccination history.
•5)Participants that received any vaccines within 14 days of screening and enrollment.
•6)Participants that received plasma, immunoglobulins, antivirals, antibodies, or blood transfusions, products, or components within 90 days prior to screening and enrollment.
•7)Participants with a fever (greater than 37.2 degree celsius under the arm) at screening or baseline.
•8)Participants with a history of immunodeficiencies or immunocompromise since, or soon after, birth.
•9)Participants with severe cardiovascular, digestive, pulmonary, endocrine, or central nerve system illness since, or soon after, birth.
•10)Participants with other clinically significant reason, as determined by the investigator, that may affect immune responses to PCV.

发起方

The National Vaccine Institute (NVI), Thailand